Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

被引：72

作者：

Green, Alexa S. ^{[1
,2
,3
,4
]}

Maciel, Thiago T. ^{[5
,6
,7
,8
]}

Hospital, Marie-Anne ^{[1
,2
,3
]}

Yin, Chae ^{[9
]}

Mazed, Fetta ^{[1
,2
,3
]}

Townsend, Elizabeth C. ^{[10
]}

Pilorge, Sylvain ^{[1
,2
,3
,11
]}

Lambert, Mireille ^{[1
,2
,3
]}

Paubelle, Etienne ^{[5
,6
,7
,8
]}

Jacquel, Arnaud ^{[11
]}

Zylbersztejn, Florence ^{[5
,6
,7
,8
]}

Decroocq, Justine ^{[5
,6
,7
,8
]}

Poulain, Laury ^{[1
,2
,3
]}

Sujobert, Pierre ^{[1
,2
,3
]}

Jacque, Nathalie ^{[1
,2
,3
]}

Adam, Kevin ^{[1
,2
,3
]}

So, Jason C. C. ^{[9
]}

Kosmider, Olivier ^{[1
,2
,3
]}

Auberger, Patrick ^{[11
]}

Hermine, Olivier ^{[5
,6
,7
,8
]}

Weinstock, David M. ^{[10
]}

Lacombe, Catherine ^{[1
,2
,3
]}

Mayeux, Patrick ^{[1
,2
,3
]}

Vanasse, Gary J. ^{[12
]}

Leung, Anskar Y. ^{[9
]}

Moura, Ivan C. ^{[5
,6
,7
,8
]}

Bouscary, Didier ^{[1
,2
,3
]}

Tamburini, Jerome ^{[1
,2
,3
]}

机构：

[1] CNRS, Inst Cochin, INSERM U1016, Dept Dev Reprod Canc,UMR 8104, F-75014 Paris, France

[2] Univ Paris 05, Fac Med, Sorbonne Paris Cite, F-75005 Paris, France

[3] Ligue Natl Canc LNCC, Equipe Labellisee, F-75013 Paris, France

[4] Charles Nicolle Univ Hosp, Dept Hematol, F-76000 Rouen, France

[5] INSERM UMR 1163, Lab Cellular & Mol Mech Hematol Disorders & Thera, F-75015 Paris, France

[6] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, F-75015 Paris, France

[7] CNRS, ERL 8254, F-75015 Paris, France

[8] Lab Excellence GR Ex, F-75015 Paris, France

[9] Univ Hong Kong, Li Ka Shing LKS Fac Med, Dept Med, Div Hematol, Hong Kong, Hong Kong, Peoples R China

[10] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[11] INSERM U1065, C3M Team 2, Cell Death Differentiat Inflammat & Canc, F-06204 Nice, France

[12] Novartis Inst BioMed Res, Cambridge, MA 02139 USA

来源：

SCIENCE ADVANCES | 2015年 / 1卷 / 08期

关键词：

D O I：

10.1126/sciadv.1500221

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide shortterm disease control, but relapse invariably occurs within months. Pim protein kinases are oncogenic FLT3-ITD targets expressed in AML cells. We show that increased Pim kinase expression is found in relapse samples from AML patients treated with FLT3 inhibitors. Ectopic Pim-2 expression induces resistance to FLT3 inhibition in both FLT3ITD- induced myeloproliferative neoplasm and AML models in mice. Strikingly, we found that Pim kinases govern FLT3-ITD signaling and that their pharmacological or genetic inhibition restores cell sensitivity to FLT3 inhibitors. Finally, dual inhibition of FLT3 and Pimkinases eradicates FLT3-ITD+ cells including primary AML cells. Concomitant Pim and FLT3 inhibition represents a promising new avenue for AML therapy.

引用

页数：13

共 50 条

[1] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Dan Xu
Yishan Chen
Ying Yang
Zhao Yin
Changfen Huang
Qiang Wang
Ling Jiang
Xuejie Jiang
Changxin Yin
Qifa Liu
Guopan Yu
Journal of Translational Medicine, 20
[2] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Xu, Dan
Chen, Yishan
Yang, Ying
Yin, Zhao
Huang, Changfen
Wang, Qiang
Jiang, Ling
Jiang, Xuejie
Yin, Changxin
Liu, Qifa
Yu, Guopan
JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
[3] FLT3 AND FLT3-ITD GENE MUTATIONS AND PROGNOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Chen, L. G.
Pei, R. Z.
Lu, Y.
Zhang, P. S.
Liu, X. H.
Du, X. H.
Chen, D.
Cao, J. J.
Li, S. Y.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (06): : 1855 - 1861
[4] PRE-CLINICAL EVALUATION OF NOVEL FLT3 INHIBITORS EFFECTIVE IN FLT3-ITD ACUTE MYELOID LEUKEMIA
Minson, Katherine
Sherick, Alisa Lee
DeRyckere, Deborah
Wang, Xiaodong
Frye, Stephen
Earp, H. Shelton, III
Graham, Doug
PEDIATRIC BLOOD & CANCER, 2014, 61 : S52 - S52
[5] A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia
Lee, Lauren
Hizukuri, Yoshiyuki
Severson, Paul
Powell, Ben
Zhang, Chao
Ma, Yan
Narahara, Maiko
Sumi, Hiroyuki
Bollag, Gideon
Levis, Mark J.
BLOOD, 2019, 134
[6] A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lee, Lauren
Hizukuri, Yoshiyuki
Severson, Paul
Powell, Benjamin
Zhang, Chao
Ma, Yan
Narahara, Maiko
Sumi, Hiroyuki
Hernandez, Daniela
Rajkhowa, Trivikram
Bollag, Gideon
Levis, Mark
HAEMATOLOGICA, 2021, 106 (04) : 1022 - 1033
[7] Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD
Dellomo, Anna J.
Baer, Maria R.
Rassool, Feyruz V.
CANCER LETTERS, 2019, 454 : 171 - 178
[8] The clinically applicable pan-Pim kinase inhibitor PIM447 sensitizes acute myeloid leukemia cells with FLT3-ITD to induction of apoptosis by FLT3 inhibitors and by topoisomerase 2 inhibitors
Doshi, Kshama A.
Baldwin, Patrick R.
Kapoor, Shivani
Baer, Maria R.
CANCER RESEARCH, 2016, 76
[9] Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia
de Macedo, Brunno Gilberto Santos
de Melo, Manuela Albuquerque
Pereira-Martins, Diego Antonio
Machado-Neto, Joao Agostinho
Traina, Fabiola
SCIENTIFIC REPORTS, 2024, 14 (01):
[10] Combined FLT3 and Pim kinase inhibitor treatment downregulates c-Myc early in apoptosis induction in acute myeloid leukemia with FLT3-ITD
Lee, Jonelle K.
Scarpa, Mario
Kapoor, Shivani
Baer, Maria R.
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →